# OnCo record nct05438329 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05438329/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05438329", "NCT05438329" ;
  schema:name "First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab and PM8002 in advanced solid tumours, run by DualityBio Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05438329/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05438329> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-07-19" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pm8002/> ;
  onco:companies <https://onco.cc/companies/dualitybio/>, <https://onco.cc/companies/biontech/> .